EA
HBIO icon

Emerald Acquisition’s Harvard Bioscience HBIO Stock Holding History

Emerald Acquisition’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$71K Hold
2,616
– – ﹤0.01% 2862
2016
Q2 		$75K Buy
+2,616
New +$83.2K ﹤0.01% 2872

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Emerald Acquisition's HBIO Position: Q3 2016 in Review

Emerald Acquisition held its Harvard Bioscience (HBIO) position steady in Q3 2016 at 2,616 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #2862.

Emerald Acquisition first reported a position in HBIO in Q2 2016 and has held it in 2 quarters since. The position peaked at $75K in Q2 2016. 69 funds tracked by Wall St. Rank hold HBIO as of Q3 2016.

  • Emerald Acquisition held 2,616 shares of Harvard Bioscience worth $71K as of Q3 2016.
  • Emerald Acquisition left its Harvard Bioscience share count unchanged in Q3 2016.
  • Harvard Bioscience made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2862 holding.
  • Emerald Acquisition first reported a position in Harvard Bioscience in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Harvard Bioscience position peaked at $75K in Q2 2016.
  • 69 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.